Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine

10 Jan 2025

Abstract excerpt

BACKGROUND: mRNA-1283 is an investigational coronavirus disease 2019 (COVID-19) mRNA vaccine encoding the receptor-binding and N-terminal domains of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in contrast to the original mRNA-1273 vaccine, which encodes the full-length spike protein. METHODS: A phase 2a, dose-ranging, observer-blind, randomized study conducted in adults (aged...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to SARS-CoV-2 detection and testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39792478
DOI: 10.1093/infdis/jiaf022

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA VaccinePMID 39792478Read ↗

Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domainsSemantic proximity Read ↗

Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2Semantic proximity Read ↗

Interim Analysis of a Phase I Randomized Clinical Trial on the Safety and Immunogenicity of the mRNA-1283 SARS-CoV-2 Vaccine in AdultsSemantic proximity Read ↗

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine — An Interim AnalysisSemantic proximity Read ↗

Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent VaccinesSemantic proximity Read ↗

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older AdultsSemantic proximity Read ↗

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.Semantic proximity Read ↗

Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)Semantic proximity Read ↗

Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal modelsSemantic proximity Read ↗

Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine BoosterSemantic proximity Read ↗

Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE TrialSemantic proximity Read ↗

Immunogenicity and Protective Efficacy of a SARS-CoV-2 mRNA Vaccine Encoding Secreted Non-Stabilized Spike Protein in MiceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.